India’s Dishman To Build $113 Million Plant For Anti-Cancer Drugs
This article was originally published in PharmAsia News
Executive Summary
Dishman Pharmaceuticals said it would invest $113.1 million in facilities in a pair of Indian economic zones where it has land. The firm said in filings with the Bombay Stock Exchange it intends to begin work in each of the zones by the end of this year. Separately, Dishman said it is in the process of constructing the largest facility in Asia, dedicated to high-potency drugs such as those to treat cancer. The facility is to be built in conjunction with its existing Bavla plant in Gujarat. (Click here for more
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.